Condition
Recurrent Extensive Stage Small Cell Lung Carcinoma
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Unknown1
Active Not Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT03672773Phase 2Active Not RecruitingPrimary
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
NCT05728619Phase 1UnknownPrimary
HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer
Showing all 2 trials